Abstract
Anticancer drug resistance remains a significant challenge in cancer therapy, impeding the effectiveness of conventional chemotherapeutic agents. This resistance can occur through various mechanisms, including drug efflux, altered drug targets, and evasion of apoptosis. This article reviews the pharmacological mechanisms behind anticancer drug resistance, focusing on cellular and molecular pathways that facilitate resistance. It also discusses recent therapeutic strategies to overcome resistance, including combination therapies, molecular targeting, and immune modulation. Understanding the molecular underpinnings of drug resistance is crucial for the development of novel therapeutic interventions that can improve patient outcomes.

This work is licensed under a Creative Commons Attribution 4.0 International License.
Copyright (c) 2024 Dr. Sarah Ahmed (Author)